Diamyd Financial Statements From 2010 to 2024
| DMYD-B Stock | SEK 13.60 0.62 4.78% |
Check Diamyd Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Diamyd Medical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Diamyd financial statements analysis is a perfect complement when working with Diamyd Medical Valuation or Volatility modules.
Diamyd |
Diamyd Medical AB Company Current Valuation Analysis
Diamyd Medical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Diamyd Medical Current Valuation | 1.06 B |
Most of Diamyd Medical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Diamyd Medical AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Diamyd Medical AB has a Current Valuation of 1.06 B. This is 92.65% lower than that of the Healthcare sector and 77.27% lower than that of the Biotechnology industry. The current valuation for all Sweden stocks is 93.65% higher than that of the company.
Diamyd Medical AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Diamyd Medical's current stock value. Our valuation model uses many indicators to compare Diamyd Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Diamyd Medical competition to find correlations between indicators driving Diamyd Medical's intrinsic value. More Info.Diamyd Medical AB is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Diamyd Medical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Diamyd Medical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Diamyd Medical Financial Statements
Diamyd Medical stakeholders use historical fundamental indicators, such as Diamyd Medical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Diamyd Medical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Diamyd Medical's assets and liabilities are reflected in the revenues and expenses on Diamyd Medical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Diamyd Medical AB. Please read more on our technical analysis and fundamental analysis pages.
Diamyd Medical AB , a diabetes company, engages in the development of combination therapies for the treatment of autoimmune diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB in April 2013. Diamyd Medical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 6 people.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Diamyd Stock
Diamyd Medical financial ratios help investors to determine whether Diamyd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diamyd with respect to the benefits of owning Diamyd Medical security.